Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2018

View Archived Issues

Patient enrollment ongoing in phase I trial of the GBM vaccine candidate VBI-1901

Novartis patents novel HBsAg secretion inhibitors

Baxter buys two hemostasis products from Mallinckrodt

The Medicines Co. closes sale of infectious disease business unit to Melinta Therapeutics

TG Therapeutics obtains rights to Jiangsu Hengrui's BTK inhibitor program

Machine learning framework allows 99% accurate ligand binding predictions

Lenvima plus Keytruda obtains FDA breakthrough therapy designation in RCC

Axsome Therapeutics announces results of IDMC interim analysis of COAST-1 and CREATE-1 trials

Novel polycomb protein EED inhibitors identified at Novartis

Roche discovers novel cannabinoid CB2 receptor ligands

Incysus submits second IND application to FDA

AVID-200 shows promise for the treatment of myelodysplastic syndrome-related anemia

Nerviano Medical Sciences patents new HsPEK inhibitors

Global Blood Therapeutics' voxelotor given breakthrough therapy designation for sickle cell disease

Molecular Partners reports initial data from phase II study of MP-0250 in multiple myeloma

Adapsyn enters into research collaboration with Pfizer

GenSight cleared by MHRA to begin phase I/II study of GS-030 gene therapy for retinitis pigmentosa

Teijin returns somavaratan rights to Versartis

European Commission extends Orkambi marketing authorization to children aged 6-11 years

Akcea Therapeutics starts phase IIb study of AKCEA-APOCIII-LRx

Axovant corrects data from pilot phase II study of nelotanserin

Advanced Proteome Therapeutics and Heidelberg Pharma advance collaboration

JTZ-951, a HIF-PH inhibitor, shows positive results for treating renal anemia

Japanese submission seeks approval of blinatumomab for relapsed or refractory B-cell precursor ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...